Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Prognostic relevance and performance characteristics of serum IGFBP-2 and PAPP-A in women with breast cancer: a long-term Danish cohort study.

Espelund U, Renehan AG, Cold S, Oxvig C, Lancashire L, Su Z, Flyvbjerg A, Frystyk J.

Cancer Med. 2018 Jun;7(6):2391-2404. doi: 10.1002/cam4.1504. Epub 2018 May 3.

2.

No tears in heaven: did the media create the pseudo-phenomenon "altitude-adjusted lachrymosity syndrome (AALS)"?

Wicks P, Lancashire L.

PeerJ. 2018 Apr 3;6:e4569. doi: 10.7717/peerj.4569. eCollection 2018.

3.

Back to the future: Alzheimer's disease heterogeneity revisited.

Au R, Piers RJ, Lancashire L.

Alzheimers Dement (Amst). 2015 Sep;1(3):368-370. No abstract available.

4.

A rat RNA-Seq transcriptomic BodyMap across 11 organs and 4 developmental stages.

Yu Y, Fuscoe JC, Zhao C, Guo C, Jia M, Qing T, Bannon DI, Lancashire L, Bao W, Du T, Luo H, Su Z, Jones WD, Moland CL, Branham WS, Qian F, Ning B, Li Y, Hong H, Guo L, Mei N, Shi T, Wang KY, Wolfinger RD, Nikolsky Y, Walker SJ, Duerksen-Hughes P, Mason CE, Tong W, Thierry-Mieg J, Thierry-Mieg D, Shi L, Wang C.

Nat Commun. 2014;5:3230. doi: 10.1038/ncomms4230.

5.

Model selection for prognostic time-to-event gene signature discovery with applications in early breast cancer data.

Ahdesmäki M, Lancashire L, Proutski V, Wilson C, Davison TS, Harkin DP, Kennedy RD.

Stat Appl Genet Mol Biol. 2013 Oct 1;12(5):619-35. doi: 10.1515/sagmb-2012-0047.

PMID:
24077567
6.

A specific PTPRC/CD45 phosphorylation event governed by stem cell chemokine CXCL12 regulates primitive hematopoietic cell motility.

Williamson AJ, Pierce A, Jaworska E, Zhou C, Aspinall-O'Dea M, Lancashire L, Unwin RD, Abraham SA, Walker MJ, Cadecco S, Spooncer E, Holyoake TL, Whetton AD.

Mol Cell Proteomics. 2013 Nov;12(11):3319-29. doi: 10.1074/mcp.M112.024604. Epub 2013 Sep 1.

7.

Drug target prediction and repositioning using an integrated network-based approach.

Emig D, Ivliev A, Pustovalova O, Lancashire L, Bureeva S, Nikolsky Y, Bessarabova M.

PLoS One. 2013 Apr 4;8(4):e60618. doi: 10.1371/journal.pone.0060618. Print 2013.

8.

Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.

Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C.

J Clin Oncol. 2012 Feb 10;30(5):525-32. doi: 10.1200/JCO.2010.33.3716. Epub 2012 Jan 17.

PMID:
22253462
9.

Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.

Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, Ranson M, Blackhall FH, Dive C.

J Thorac Oncol. 2012 Feb;7(2):306-15. doi: 10.1097/JTO.0b013e31823c5c16.

10.

Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.

Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, Ranson M, Dive C, Blackhall FH.

J Clin Oncol. 2011 Apr 20;29(12):1556-63. doi: 10.1200/JCO.2010.28.7045. Epub 2011 Mar 21.

PMID:
21422424
11.

A proteomic approach combining MS and bioinformatic analysis for the detection and identification of biomarkers of administration of exogenous human growth hormone in humans.

Boateng J, Kay R, Lancashire L, Brown P, Velloso C, Bouloux P, Teale P, Roberts J, Rees R, Ball G, Harridge S, Goldspink G, Creaser C.

Proteomics Clin Appl. 2009 Aug;3(8):912-22. doi: 10.1002/prca.200800190. Epub 2009 Jul 30.

PMID:
21136995
12.

Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.

Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C, Blackhall FH.

Am J Pathol. 2009 Aug;175(2):808-16. doi: 10.2353/ajpath.2009.090078. Epub 2009 Jul 23.

13.

Quantitative proteomics analysis demonstrates post-transcriptional regulation of embryonic stem cell differentiation to hematopoiesis.

Williamson AJ, Smith DL, Blinco D, Unwin RD, Pearson S, Wilson C, Miller C, Lancashire L, Lacaud G, Kouskoff V, Whetton AD.

Mol Cell Proteomics. 2008 Mar;7(3):459-72. Epub 2007 Nov 27.

14.

Characterization of biomarkers in polycystic ovary syndrome (PCOS) using multiple distinct proteomic platforms.

Matharoo-Ball B, Hughes C, Lancashire L, Tooth D, Ball G, Creaser C, Elgasim M, Rees R, Layfield R, Atiomo W.

J Proteome Res. 2007 Aug;6(8):3321-8. Epub 2007 Jun 29.

PMID:
17602513
15.

Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach.

Matharoo-Ball B, Ratcliffe L, Lancashire L, Ugurel S, Miles AK, Weston DJ, Rees R, Schadendorf D, Ball G, Creaser CS.

Proteomics Clin Appl. 2007 Jun;1(6):605-20. doi: 10.1002/prca.200700022.

PMID:
21136712
16.
18.

Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients.

Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D.

J Clin Oncol. 2005 Aug 1;23(22):5088-93.

PMID:
16051955
19.

Supplemental Content

Loading ...
Support Center